These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26163066)

  • 1. PML in DMF-treated patients with normal lymphocytes: Worried well or well to be worried?
    Carruthers RL; Healy BC
    Mult Scler; 2016 Mar; 22(3):394-5. PubMed ID: 26163066
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
    Van Schependom J; Gielen J; Laton J; Nagels G
    Mult Scler; 2016 Mar; 22(3):389-92. PubMed ID: 26199353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
    Jordan AL; Yang J; Fisher CJ; Racke MK; Mao-Draayer Y
    Mult Scler; 2022 Jan; 28(1):7-15. PubMed ID: 32808554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T-cells exhaustion.
    Garcia J; Hendel-Chavez H; De-Goer MG; L'Honneur AS; Dubessy AL; Taoufik Y; Stankoff B
    Mult Scler; 2021 Apr; 27(4):640-644. PubMed ID: 32686582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.
    Bartsch T; Rempe T; Wrede A; Leypoldt F; Brück W; Adams O; Rohr A; Jansen O; Wüthrich C; Deuschl G; Koralnik IJ
    Ann Neurol; 2015 Oct; 78(4):501-14. PubMed ID: 26150206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding spectrum of opportunistic infections associated with dimethyl fumarate.
    Kim T; Croteau D; Brinker A; Jones DE; Lee PR; Kortepeter CM
    Mult Scler; 2021 Jul; 27(8):1301-1305. PubMed ID: 33300850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.
    Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J
    Mult Scler; 2019 Oct; 25(12):1682-1685. PubMed ID: 31208265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
    Lehmann-Horn K; Penkert H; Grein P; Leppmeier U; Teuber-Hanselmann S; Hemmer B; Berthele A
    Neurology; 2016 Jul; 87(4):440-1. PubMed ID: 27343070
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Faulkner M
    Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimethyl fumarate associated lymphopenia in clinical practice.
    Longbrake EE; Cross AH
    Mult Scler; 2015 May; 21(6):796-7. PubMed ID: 25432948
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical commentary for "Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T-cells exhaustion".
    Berger JR
    Mult Scler; 2021 Apr; 27(4):644-645. PubMed ID: 32686584
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manufacturer's response to case reports of PML.
    Sweetser MT; Dawson KT; Bozic C
    N Engl J Med; 2013 Apr; 368(17):1659-61. PubMed ID: 23614605
    [No Abstract]   [Full Text] [Related]  

  • 14. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
    Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis.
    Stoppe M; Thomä E; Liebert UG; Major EO; Hoffmann KT; Claßen J; Then Bergh F
    J Neurol; 2014 May; 261(5):1021-4. PubMed ID: 24638202
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
    Khatri BO; Garland J; Berger J; Kramer J; Sershon L; Olapo T; Sesing J; Dukic M; Rehn E
    Mult Scler Relat Disord; 2015 Jul; 4(4):377-9. PubMed ID: 26195059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PML in Patients Treated with Dimethyl Fumarate.
    Balak D; Hajdarbegovic E
    N Engl J Med; 2015 Aug; 373(6):582-3. PubMed ID: 26244325
    [No Abstract]   [Full Text] [Related]  

  • 18. More on PML in Patients Treated with Dimethyl Fumarate.
    Reich K; Hartung HP; Lebwohl M
    N Engl J Med; 2016 Jan; 374(3):294-5. PubMed ID: 26789900
    [No Abstract]   [Full Text] [Related]  

  • 19. PML in Patients Treated with Dimethyl Fumarate.
    van Kester MS; Bouwes Bavinck JN; Quint KD
    N Engl J Med; 2015 Aug; 373(6):583-4. PubMed ID: 26244326
    [No Abstract]   [Full Text] [Related]  

  • 20. PML in Patients Treated with Dimethyl Fumarate.
    Nieuwkamp DJ; Murk JL; van Oosten BW
    N Engl J Med; 2015 Aug; 373(6):584. PubMed ID: 26244324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.